ketamine has been researched along with Adverse Drug Event in 36 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketamine is frequently used in the management of refractory chronic pain." | 8.98 | [Ketamine and chronic pain: A narrative review of its efficacy and its adverse events]. ( Micallef, J; Morel, V; Pickering, G, 2018) |
| "Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety." | 8.31 | Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. ( Andriola, I; Barlati, S; Bassetti, R; Chiappini, S; Clerici, M; d'Andrea, G; De Filippis, S; Dell'Osso, B; Di Nicola, M; Martinotti, G; Pettorruso, M; Sensi, S; Vita, A, 2023) |
| "This multi-center, retrospective cohort study evaluated adult patients who received analgesic and sub-dissociative dose ketamine for the management of acute pain between May 5, 2018, and August 30, 2021, in 21 emergency departments at academic, community, and critical access hospitals across four states." | 8.31 | Efficacy of analgesic and sub-dissociative dose ketamine for acute pain in the emergency department. ( Beaudrie-Nunn, AN; Bellolio, F; Canterbury, EA; Mara, KC; Wieruszewski, ED; Woods, EJ, 2023) |
| "To report on an unusual case of ketamine-precipitated syndrome of inappropriate antidiuretic hormone secretion (SIADH) in an individual managed by an outpatient pain specialty team." | 8.12 | Ketamine-precipitated syndrome of inappropriate antidiuretic hormone secretion in a patient with persistent lumbar pain: a case report. ( Lau, A; van Bockxmeer, JJ; Varshney, V, 2022) |
| "Esketamine is the S-enantiomer of racemic ketamine and has been approved by the Food and Drug Administration for the management of treatment resistant depression, demonstrating effective and long-lasting benefits." | 8.12 | Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice. ( Do, A; Giacobbe, P; Gutierrez, G; Hawken, E; Karthikeyan, G; Lam, RW; Milev, R; Ravindran, N; Rosenblat, J; Schaffer, A; Swainson, J; Vazquez, G, 2022) |
| "The xylazine/ketamine anesthesia test is widely used as a predictor of the emetic potential of pharmacological compounds in rats." | 7.91 | Validation of the xylazine/ketamine anesthesia test as a predictor of the emetic potential of pharmacological compounds in rats. ( Bonassoli, VT; Heckman, PRA; Nelissen, E; Prickaerts, J; Suay, D; van Goethem, NP; van Hagen, BTJ; Wouters, C, 2019) |
| " The most common treatment-emergent adverse events associated with ketamine/esketamine are dissociation, anxiety, nausea, increased blood pressure, and headache." | 6.72 | Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders. ( Cao, B; Ceban, F; Chau, EH; Gill, H; Ho, RC; Kratiuk, K; Kumar, A; Lee, JG; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Swainson, J, 2021) |
| " A literature review was performed to ascertain potential side effects and/or adverse events when using ketamine for analgesia purposes." | 6.55 | Ketamine for Pain Management-Side Effects & Potential Adverse Events. ( Allen, CA; Ivester, JR, 2017) |
| "Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist first developed as an anesthetic, has shown significant promise as a medication with rapid antidepressant properties in treatment-resistant depression." | 5.41 | The antidepressant actions of ketamine and its enantiomers. ( Henter, ID; Johnston, JN; Zarate, CA, 2023) |
| "In non-intubated general anesthesia, the combination of subclinical doses of esketamine and propofol did reduce circulatory and respiratory depression, injection pain, and other adverse effects, while the incidence of esketamine's own side effects such as neuropsychiatric reactions did not increase, and the combination of the two did not cause the occurrence of new and more serious adverse reactions, and the combination of the two was safe and effective." | 5.41 | Analysis of the efficacy of subclinical doses of esketamine in combination with propofol in non-intubated general anesthesia procedures - a systematic review and meta-analysis. ( Chen, H; Ding, X; Fu, Q; Li, P; Liu, Q; Xiang, G; Xu, L, 2023) |
| "A prospective, randomized, controlled, double-blind clinical trial to assess the effect of tramadol and ketamine, 50 mg, added to ropivacaine in brachial plexus anesthesia." | 5.19 | Does the addition of tramadol and ketamine to ropivacaine prolong the axillary brachial plexus block? ( Senel, AC; Timurkaynak, A; Ukinc, O, 2014) |
| "Ketamine is frequently used in the management of refractory chronic pain." | 4.98 | [Ketamine and chronic pain: A narrative review of its efficacy and its adverse events]. ( Micallef, J; Morel, V; Pickering, G, 2018) |
| "Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety." | 4.31 | Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. ( Andriola, I; Barlati, S; Bassetti, R; Chiappini, S; Clerici, M; d'Andrea, G; De Filippis, S; Dell'Osso, B; Di Nicola, M; Martinotti, G; Pettorruso, M; Sensi, S; Vita, A, 2023) |
| "This multi-center, retrospective cohort study evaluated adult patients who received analgesic and sub-dissociative dose ketamine for the management of acute pain between May 5, 2018, and August 30, 2021, in 21 emergency departments at academic, community, and critical access hospitals across four states." | 4.31 | Efficacy of analgesic and sub-dissociative dose ketamine for acute pain in the emergency department. ( Beaudrie-Nunn, AN; Bellolio, F; Canterbury, EA; Mara, KC; Wieruszewski, ED; Woods, EJ, 2023) |
| "To report on an unusual case of ketamine-precipitated syndrome of inappropriate antidiuretic hormone secretion (SIADH) in an individual managed by an outpatient pain specialty team." | 4.12 | Ketamine-precipitated syndrome of inappropriate antidiuretic hormone secretion in a patient with persistent lumbar pain: a case report. ( Lau, A; van Bockxmeer, JJ; Varshney, V, 2022) |
| "Esketamine is the S-enantiomer of racemic ketamine and has been approved by the Food and Drug Administration for the management of treatment resistant depression, demonstrating effective and long-lasting benefits." | 4.12 | Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice. ( Do, A; Giacobbe, P; Gutierrez, G; Hawken, E; Karthikeyan, G; Lam, RW; Milev, R; Ravindran, N; Rosenblat, J; Schaffer, A; Swainson, J; Vazquez, G, 2022) |
| "The xylazine/ketamine anesthesia test is widely used as a predictor of the emetic potential of pharmacological compounds in rats." | 3.91 | Validation of the xylazine/ketamine anesthesia test as a predictor of the emetic potential of pharmacological compounds in rats. ( Bonassoli, VT; Heckman, PRA; Nelissen, E; Prickaerts, J; Suay, D; van Goethem, NP; van Hagen, BTJ; Wouters, C, 2019) |
| "Esketamine was approved for adults with treatment-resistant depression (TRD) in conjunction with an oral antidepressant, and for treating depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior." | 2.82 | Craving and addictive potential of esketamine as side effects? ( Orsolini, L; Salvi, V; Volpe, U, 2022) |
| " The most common treatment-emergent adverse events associated with ketamine/esketamine are dissociation, anxiety, nausea, increased blood pressure, and headache." | 2.72 | Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders. ( Cao, B; Ceban, F; Chau, EH; Gill, H; Ho, RC; Kratiuk, K; Kumar, A; Lee, JG; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Swainson, J, 2021) |
| " Our aim was to develop a comprehensive Ketamine Side Effect Tool (KSET) to capture acute and longer-term side effects associated with repeated ketamine treatments." | 2.66 | Development of the Ketamine Side Effect Tool (KSET). ( Bayes, AJ; Dong, V; Fam, J; Fraguas, R; Gálvez, V; Glue, P; Loo, CK; Martin, D; McLoughlin, DM; McShane, R; Murrough, JW; Riva-Posse, P; Schoevers, R; Short, B; Vulovic, V; Zarate, CA, 2020) |
| " A literature review was performed to ascertain potential side effects and/or adverse events when using ketamine for analgesia purposes." | 2.55 | Ketamine for Pain Management-Side Effects & Potential Adverse Events. ( Allen, CA; Ivester, JR, 2017) |
| " Results Potential avenues investigated to minimise psychotomimetic effects associated with ketamine administration include the following: (1) altering dosing and infusion rates; (2) route of administration; (3) enantiomer choice; (4) co-administration with mood stabilisers of antipsychotics; and (5) use of alternative N-methyl-d-aspartate (NMDA)-modulating agents." | 2.55 | Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review. ( Cha, DS; Cooper, MD; Kakar, R; Lee, Y; McIntyre, RS; Rosenblat, JD, 2017) |
| "We conducted a systematic review and meta-analysis to evaluate the incidence of adverse events in the emergency department (ED) during procedural sedation in the paediatric population." | 2.53 | Incidence of adverse events in paediatric procedural sedation in the emergency department: a systematic review and meta-analysis. ( Anderson, JL; Barrionuevo, P; Bellolio, MF; Erwin, PJ; Gilani, WI; Hess, EP; Murad, MH; Puls, HA; Wang, Z, 2016) |
| "We recommend the Ketamine Side Effect Tool (KSET) as a comprehensive safety monitoring tool for acute and longer term side effects." | 1.72 | The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry. ( Bayes, A; Brunoni, AR; Fam, J; Galvez, V; Glue, P; Loo, CK; Martin, D; McLoughlin, DM; McShane, R; Murrough, JW; Parikh, S; Park, L; Riva-Posse, P; Schoevers, R; Short, B; Tor, PC; Veraart, J; Zarate, CA, 2022) |
| "Using the FDA Adverse Event Reporting System (FAERS) database (March 2019-March 2020), we analysed esketamine-related adverse events (AEs) to detect and characterize relevant safety signals." | 1.62 | Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. ( Barbui, C; Gastaldon, C; Kane, JM; Raschi, E; Schoretsanitis, G, 2021) |
| "Ketamine was the sole drug administered in 156/194 (80." | 1.62 | Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports. ( Castiglione, F; Chiappini, S; Salonia, A; Schifano, F; Schifano, N, 2021) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.78) | 29.6817 |
| 2010's | 13 (36.11) | 24.3611 |
| 2020's | 19 (52.78) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Karakatsoulis, GN | 1 |
| Tsapakis, EM | 1 |
| Fountoulakis, KN | 1 |
| van Bockxmeer, JJ | 1 |
| Lau, A | 1 |
| Varshney, V | 1 |
| Bayes, A | 1 |
| Short, B | 2 |
| Zarate, CA | 3 |
| Park, L | 1 |
| Murrough, JW | 2 |
| McLoughlin, DM | 2 |
| Riva-Posse, P | 2 |
| Schoevers, R | 2 |
| Veraart, J | 1 |
| Parikh, S | 1 |
| Glue, P | 2 |
| Fam, J | 2 |
| McShane, R | 2 |
| Galvez, V | 2 |
| Martin, D | 2 |
| Tor, PC | 1 |
| Brunoni, AR | 1 |
| Loo, CK | 2 |
| Orsolini, L | 1 |
| Salvi, V | 1 |
| Volpe, U | 1 |
| Vazquez, G | 1 |
| Gutierrez, G | 1 |
| Rosenblat, J | 1 |
| Schaffer, A | 1 |
| Swainson, J | 2 |
| Karthikeyan, G | 1 |
| Ravindran, N | 1 |
| Lam, RW | 1 |
| Do, A | 1 |
| Giacobbe, P | 1 |
| Hawken, E | 1 |
| Milev, R | 1 |
| Palamar, JJ | 1 |
| Johnston, JN | 1 |
| Henter, ID | 1 |
| Chiappini, S | 2 |
| d'Andrea, G | 1 |
| De Filippis, S | 1 |
| Di Nicola, M | 1 |
| Andriola, I | 1 |
| Bassetti, R | 1 |
| Barlati, S | 1 |
| Pettorruso, M | 1 |
| Sensi, S | 1 |
| Clerici, M | 1 |
| Dell'Osso, B | 1 |
| Vita, A | 1 |
| Martinotti, G | 1 |
| Beaudrie-Nunn, AN | 1 |
| Wieruszewski, ED | 1 |
| Woods, EJ | 1 |
| Bellolio, F | 1 |
| Mara, KC | 1 |
| Canterbury, EA | 1 |
| Chen, H | 1 |
| Ding, X | 1 |
| Xiang, G | 1 |
| Xu, L | 1 |
| Liu, Q | 1 |
| Fu, Q | 1 |
| Li, P | 1 |
| Bozymski, KM | 1 |
| Crouse, EL | 1 |
| Titus-Lay, EN | 1 |
| Ott, CA | 1 |
| Nofziger, JL | 1 |
| Kirkwood, CK | 1 |
| Zhong, L | 1 |
| Li, H | 1 |
| Zhao, B | 1 |
| Dong, V | 1 |
| Vulovic, V | 1 |
| Bayes, AJ | 1 |
| Fraguas, R | 1 |
| Gastaldon, C | 1 |
| Raschi, E | 1 |
| Kane, JM | 1 |
| Barbui, C | 1 |
| Schoretsanitis, G | 1 |
| Schifano, N | 1 |
| Castiglione, F | 1 |
| Salonia, A | 1 |
| Schifano, F | 1 |
| Zhan, Z | 1 |
| Wang, X | 1 |
| Chen, Q | 1 |
| Xiao, Z | 1 |
| Zhang, B | 1 |
| Meissner, K | 1 |
| Henthorn, TK | 1 |
| Ceban, F | 1 |
| Rosenblat, JD | 2 |
| Kratiuk, K | 1 |
| Lee, Y | 2 |
| Rodrigues, NB | 1 |
| Gill, H | 1 |
| Subramaniapillai, M | 1 |
| Nasri, F | 1 |
| Lui, LMW | 1 |
| Lipsitz, O | 1 |
| Kumar, A | 1 |
| Lee, JG | 1 |
| Chau, EH | 1 |
| Cao, B | 1 |
| Lin, K | 1 |
| Ho, RC | 1 |
| Mansur, RB | 1 |
| McIntyre, RS | 2 |
| Allen, CA | 1 |
| Ivester, JR | 1 |
| Hurwitz, J | 1 |
| Pickering, G | 1 |
| Morel, V | 1 |
| Micallef, J | 1 |
| Nelissen, E | 1 |
| van Goethem, NP | 1 |
| Bonassoli, VT | 1 |
| Heckman, PRA | 1 |
| van Hagen, BTJ | 1 |
| Suay, D | 1 |
| Wouters, C | 1 |
| Prickaerts, J | 1 |
| Senel, AC | 1 |
| Ukinc, O | 1 |
| Timurkaynak, A | 1 |
| Cooper, MD | 1 |
| Cha, DS | 1 |
| Kakar, R | 1 |
| Mora, AG | 1 |
| Ganem, VJ | 1 |
| Ervin, AT | 1 |
| Maddry, JK | 1 |
| Bebarta, VS | 1 |
| Bellolio, MF | 1 |
| Puls, HA | 1 |
| Anderson, JL | 1 |
| Gilani, WI | 1 |
| Murad, MH | 1 |
| Barrionuevo, P | 1 |
| Erwin, PJ | 1 |
| Wang, Z | 1 |
| Hess, EP | 1 |
| Hashimoto, K | 1 |
| Wood, DM | 1 |
| Greene, SL | 1 |
| Dargan, PI | 1 |
| Berde, C | 1 |
| Cairns, B | 1 |
| Wardell, WM | 1 |
| Tsianco, MC | 1 |
| Anavekar, SN | 1 |
| Davis, HT | 1 |
| Ndiritu, CG | 1 |
| Enos, LR | 1 |
| Robertson, DM | 1 |
12 reviews available for ketamine and Adverse Drug Event
| Article | Year |
|---|---|
[The role of ketamine in the treatment of treatment-resistant bipolar depression].
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Drug- | 2021 |
Craving and addictive potential of esketamine as side effects?
Topics: Adult; Bupropion; Craving; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactio | 2022 |
The antidepressant actions of ketamine and its enantiomers.
Topics: Antidepressive Agents; Depression; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine | 2023 |
Analysis of the efficacy of subclinical doses of esketamine in combination with propofol in non-intubated general anesthesia procedures - a systematic review and meta-analysis.
Topics: Anesthesia, General; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine; Pain; Propof | 2023 |
Esketamine: A Novel Option for Treatment-Resistant Depression.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Blood Pressure; Depr | 2020 |
Development of the Ketamine Side Effect Tool (KSET).
Topics: Chronic Pain; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine; Reproducibility of | 2020 |
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders.
Topics: Administration, Intranasal; Administration, Intravenous; Antidepressive Agents; Anxiety; Disease Man | 2021 |
Ketamine for Pain Management-Side Effects & Potential Adverse Events.
Topics: Analgesics; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine; Pain; Pain Management | 2017 |
[Ketamine and chronic pain: A narrative review of its efficacy and its adverse events].
Topics: Analgesics; Chronic Pain; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine; Pain Ma | 2018 |
Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review.
Topics: Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions; Excitatory Amino Acid A | 2017 |
Incidence of adverse events in paediatric procedural sedation in the emergency department: a systematic review and meta-analysis.
Topics: Anesthetics, Dissociative; Child; Conscious Sedation; Drug-Related Side Effects and Adverse Reaction | 2016 |
The eye and adverse drug effects. Some selected considerations.
Topics: Acetazolamide; Amyl Nitrite; Anesthesia; Chloramphenicol; Chloroquine; Contraceptives, Oral; Dexamet | 1972 |
1 trial available for ketamine and Adverse Drug Event
| Article | Year |
|---|---|
Does the addition of tramadol and ketamine to ropivacaine prolong the axillary brachial plexus block?
Topics: Adult; Amides; Analgesics, Opioid; Anesthesia; Brachial Plexus; Brachial Plexus Block; Double-Blind | 2014 |
23 other studies available for ketamine and Adverse Drug Event
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Ketamine-precipitated syndrome of inappropriate antidiuretic hormone secretion in a patient with persistent lumbar pain: a case report.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hyponatremia; Inappropriate ADH Syndrome; K | 2022 |
The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry.
Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Drug-Re | 2022 |
Unintentional Ketamine Overdose in the Operating Room - Mixing Up the Ampules.
Topics: Analgesics, Opioid; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine; Operating Roo | 2022 |
Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2022 |
Adverse drug effects as a deterrent against willingness to use in the future among nightclub/festival attendees.
Topics: Adult; Drug-Related Side Effects and Adverse Reactions; Holidays; Humans; Illicit Drugs; Ketamine; M | 2023 |
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
Topics: Administration, Intranasal; Adult; Antidepressive Agents; Comorbidity; Depression; Depressive Disord | 2023 |
Efficacy of analgesic and sub-dissociative dose ketamine for acute pain in the emergency department.
Topics: Acute Pain; Adult; Analgesics; Analgesics, Opioid; Double-Blind Method; Drug-Related Side Effects an | 2023 |
Comparison of Ketamine Alone and Subanesthetic Dose of Ketamine-Fentanyl for Regional Anesthesia in Children.
Topics: Administration, Intravenous; Analgesia; Anesthesia, Intravenous; Child; Child, Preschool; Drug-Relat | 2020 |
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Female; Hu | 2021 |
Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; Ke | 2021 |
Comparative efficacy and side-effect profile of ketamine and esketamine in the treatment of unipolar and bipolar depression: protocol for a systematic review and network meta-analysis.
Topics: Bipolar Disorder; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine; Meta-Analysis a | 2021 |
How relevant is stereoselectivity to the side-effects of ketamine?
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Iatrogenic Disease; Ketamine; Stereoisomeri | 2021 |
Can We Finally Dispense With Ketamine's Many Myths?
Topics: Anesthetics, Dissociative; Antidepressive Agents; Drug-Related Side Effects and Adverse Reactions; E | 2018 |
Validation of the xylazine/ketamine anesthesia test as a predictor of the emetic potential of pharmacological compounds in rats.
Topics: Anesthesia; Animals; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; | 2019 |
En Route Use of Analgesics in Nonintubated, Critically Ill Patients Transported by U.S. Air Force Critical Care Air Transport Teams.
Topics: Adult; Aerospace Medicine; Afghan Campaign 2001-; Air Ambulances; Analgesics; Critical Care; Critica | 2016 |
Detrimental Side Effects of Repeated Ketamine Infusions in the Brain.
Topics: Brain; Depressive Disorder, Treatment-Resistant; Drug-Related Side Effects and Adverse Reactions; Hu | 2016 |
Five-year trends in self-reported recreational drugs associated with presentation to a UK emergency department with suspected drug-related toxicity.
Topics: Amphetamine-Related Disorders; Cocaine-Related Disorders; Drug-Related Side Effects and Adverse Reac | 2013 |
Developmental pharmacology across species: promise and problems.
Topics: Adult; Age Factors; Analgesics; Anesthetics; Animals; Animals, Laboratory; Animals, Newborn; Brain; | 2000 |
Postmarketing surveillance of new drugs: II. Case studies.
Topics: Azauridine; Bacteriuria; Contraceptives, Oral; Costs and Cost Analysis; Double-Blind Method; Drug-Re | 1979 |
Adverse reactions to drugs in a veterinary hospital.
Topics: Amphotericin B; Anaphylaxis; Animals; Cat Diseases; Cats; Cattle; Cattle Diseases; Chloral Hydrate; | 1977 |